Autopsy report · NCT02219373

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

“Study was withdrawn for feasibility-related concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Boston Children's Hospital

Sponsor type

University, hospital or other

Conditions

Pediatric Chronic Neuropathic Pain

Interventions

Gabapentin; Oxcarbazepine; Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
  “Study was withdrawn due to scientific and business considerations.” (84% match in meaning)
• Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
  “This study was withdrawn for business reasons.” (83% match in meaning)
• Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
  “Due to limited funding, the study is now being withdrawn.” (78% match in meaning)
• Maxi-Analgesic Osteoarthritis (OA) Study
  “The study was withdrawn for administrative reason” (77% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.